Study Evaluating IMA-026 in Healthy Subjects
Completed · Phase 1
Conditions studied: Healthy
In brief
To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IMA-026 administered subcutaneously (SC) or intravenously (IV) in healthy adults.
Key facts
- Study ID
- NCT00517348
- Run by
- Wyeth is now a wholly owned subsidiary of Pfizer
- People needed
- 50
- Starts
- 2007-09-01
- Expected to finish
- 2008-07-01
- Last updated by the study team
- 2009-06-25
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.
Where it is running
- Study site — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.